PT  - JOURNAL ARTICLE
AU  - B. S. Thomas
AU  - N. A. Marks
TI  - Estimating the Case Fatality Ratio for COVID-19 using a Time-Shifted Distribution Analysis
AID  - 10.1101/2020.10.25.20216671
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.25.20216671
4099  - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20216671.short
4100  - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20216671.full
AB  - Estimating the case fatality ratio (CFR) for COVID-19 is an important aspect of public health. However, calculating CFR accurately is problematic early in a novel disease outbreak, due to uncertainties regarding the time course of disease and difficulties in diagnosis and reporting of cases. In this work, we present a simple method for calculating the case fatality ratio using only public case and death data over time by exploiting the correspondence between the time distributions of cases and deaths. The time-shifted distribution (TSD) analysis generates two parameters of interest: the delay time between reporting of cases and deaths and the case fatality ratio. These parameters converge reliably over time once the exponential growth phase has finished. Analysis is performed for early COVID-19 outbreaks in many countries, and we discuss corrections to CFR values using excess-death and seroprevalence data to estimate the infection fatality ratio (IFR). While CFR values range from 0.2-20% in different countries, estimates for IFR are mostly around 0.5-0.8% for countries that experienced moderate outbreaks and 1-3% for severe outbreaks. The simplicity and transparency of TSD analysis enhance its usefulness in characterizing a new disease as well as the state of the health and reporting systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was provided by Curtin University and The Government of Western Australia through the Department of Jobs, Tourism, Science and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used this study are publicly available at the links below. https://github.com/pomber/covid19 https://www.worldometers.info/coronavirus/ https://github.com/imdevskp/sars-2003-outbreak-data-webscraping-code https://github.com/TheEconomist/covid-19-excess-deaths-tracker https://ourworldindata.org/coronavirus-testing